https://www.openbell.ai/ 2026-10-26T12:42:08.525Z hourly 1.0 https://www.openbell.ai/support 2026-10-26T12:42:08.525Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-26T12:42:08.525Z monthly 0.5 https://www.openbell.ai/terms 2026-10-26T12:42:08.525Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-26T12:42:08.525Z hourly 0.8 https://www.openbell.ai/news/META:1793017868407 2026-10-26T12:31:08.407Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $META Sentiment: Bearish. Theme: Meta’s massive stock offering to fund AI expansion is drawing jokes about shareholder dilution. https://www.openbell.ai/news/NVDA:1793017865412 2026-10-26T12:31:05.412Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $NVDA Neutral overall: discussions focus on defense needs versus drone swarms, SpaceX’s $40 billion AI-chip purchase, South Korea’s unusually large current-account surplus, and the S&P 500’s mixed breadth despite a recent decline. https://www.openbell.ai/news/ESLT:1793016125000 2026-10-26T12:02:05.000Z daily 0.9 https://cdn.brandfetch.io/ESLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Elbit Systems Awarded $200 Million Contracts for Airborne ISTAR and Training Solutions in Asia-Pacific Elbit Systems was awarded contracts worth approximately $200 million from an Asia-Pacific customer for airborne ISTAR payloads, training system support, upgrades, and advanced head-up display systems. The contracts are scheduled to be performed over up to five years and add to the company’s backlog, supporting multi-year revenue stability. https://www.openbell.ai/news/BAK:1793016102000 2026-10-26T12:01:42.000Z daily 0.9 https://cdn.brandfetch.io/BAK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Braskem Nears Debt Restructuring Agreement Braskem is in advanced discussions with creditors and shareholders to restructure roughly $11 billion of debt. The proposal may include an equity offering and a concurrent debt-to-equity swap, alongside a potential capital injection of $4 billion to $5 billion. The company has not officially commented on the negotiations. https://www.openbell.ai/news/PLUS:1793016101000 2026-10-26T12:01:41.000Z daily 0.9 https://cdn.brandfetch.io/PLUS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Plus500 Reports Strong Q3 2026 Trading Update Plus500 reported Q3 2026 revenue of $203.2 million, up 11% year-on-year, and EBITDA of $88.4 million, up 7%, with a 44% EBITDA margin. New customers increased 27% to 28,747. The company said it acquired broker-dealers in the US and Brazil to broaden market access and product offerings. The Board expects full-year 2026 revenue and EBITDA to exceed current market expectations. https://www.openbell.ai/news/KCR:1793016096000 2026-10-26T12:01:36.000Z daily 0.9 https://cdn.brandfetch.io/KCR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Konecranes Reports Q3 2026 Financial Results Konecranes reported third-quarter 2026 revenue of $1.27 billion, up 9.68% from $1.16 billion a year earlier. Earnings per share rose to $0.14 from $0.10 in the prior-year quarter. The quarter ended September 30, 2026. https://www.openbell.ai/news/BOH:1793014368000 2026-10-26T11:32:48.000Z daily 0.9 https://cdn.brandfetch.io/BOH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bank of Hawaii Reports Q3 2026 Financial Results Bank of Hawaii reported third-quarter 2026 revenue of $198.8 million, up 6.8% year over year but below analyst estimates of about $202.6 million to $202.8 million. GAAP EPS was $1.49, 1.5% below the $1.51 consensus estimate. Net interest income was $156.1 million, net interest margin was 2.8%, and the efficiency ratio was 56.5%; CEO Jim Polk cited continued expense discipline. https://www.openbell.ai/news/ORKA:1793014333000 2026-10-26T11:32:13.000Z daily 0.9 https://cdn.brandfetch.io/ORKA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial Oruka Therapeutics reported positive Week 16 results from its ongoing EVERLAST-B trial of ORKA-001, a biologic candidate for moderate-to-severe plaque psoriasis. The company said the findings mark a clinical milestone as it develops extended half-life monoclonal antibodies intended to combine high efficacy with infrequent dosing. Oruka had planned a conference call to discuss the results; the article provides no specific efficacy figures or stock-price impact. https://www.openbell.ai/news/RRC:1793014318000 2026-10-26T11:31:58.000Z daily 0.9 https://cdn.brandfetch.io/RRC/w/400/h/400?c=1idopYfmtR7ZKg8QMud EQT Corporation Announces Definitive Agreement to Acquire Range Resources Corporation EQT Corporation and Range Resources Corporation announced a definitive all-stock merger agreement on October 26, 2026. Range shareholders will receive 0.987 EQT shares for each Range share, and the deal is expected to close in the first quarter of 2027, subject to regulatory and shareholder approvals. After closing, two Range representatives will join EQT’s board; the companies say the combination is intended to create a leading U.S. natural gas producer. https://www.openbell.ai/news/META:1793014301000 2026-10-26T11:31:41.000Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Meta Announces Public Offerings of Depositary Shares and Class A Common Stock Meta Platforms launched concurrent underwritten public offerings of 250 million Series A depositary shares and $22.5 billion of Class A common stock. Each depositary share represents a 1/20th interest in newly issued Series A Mandatory Convertible Preferred Stock, while the common-stock offering is being conducted in connection with forward sale agreements. Meta said the offerings will support continued investment in AI infrastructure and personal superintelligence. https://www.openbell.ai/news/AZN:1793012516000 2026-10-26T11:01:56.000Z daily 0.9 https://cdn.brandfetch.io/AZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud AstraZeneca and HUTCHMED Present Positive Phase III Data for Lung Cancer Combination Therapy AstraZeneca and HUTCHMED presented Phase III data at the ESMO 2026 congress for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib) in first-line EGFR-mutated non-small cell lung cancer. The results indicated the combination reduced disease progression. The companies jointly developed ORPATHYS, with AstraZeneca responsible for commercialization, highlighting their ongoing oncology collaboration. https://www.openbell.ai/news/2010:1793012514000 2026-10-26T11:01:54.000Z daily 0.9 https://cdn.brandfetch.io/2010/w/400/h/400?c=1idopYfmtR7ZKg8QMud Saudi Basic Industries Corp. Reports Third-Quarter Financial Results Saudi Basic Industries Corp. (SABIC) reported third-quarter 2026 net profit of 499 million riyals ($133 million), up from 434 million riyals a year earlier, while revenue fell to 28.17 billion riyals from 29.08 billion. Profit growth reflected higher average selling prices and a 1.62 billion-riyal improvement in results from associates and joint ventures, including reversal of an impairment on its Clariant investment. These gains were partly offset by a 916 million-riyal increase in selling and distribution expenses, which SABIC attributed to supply-chain disruptions and shipping tensions around the Strait of Hormuz. https://www.openbell.ai/news/BMY:1793010716000 2026-10-26T10:31:56.000Z daily 0.9 https://cdn.brandfetch.io/BMY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bristol Myers Squibb and SystImmune Announce Positive Phase 3 Results for Izalontamab Brengitecan in NSCLC Bristol Myers Squibb and SystImmune reported positive interim Phase 3 PANKU-Lung01 results for izalontamab brengitecan in previously treated EGFR-mutated non-small cell lung cancer. The EGFRxHER3 antibody-drug conjugate doubled median progression-free survival compared with chemotherapy. BMS is continuing to develop the drug within its oncology portfolio, citing its potential to address unmet needs across multiple tumor types. https://www.openbell.ai/news/BA:1793010711000 2026-10-26T10:31:51.000Z daily 0.9 https://cdn.brandfetch.io/BA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Boeing 777 Freighter Production Stalled by Supplier Dispute Boeing’s 777 freighter production has reportedly been halted for two months amid a dispute with a supplier. The stoppage is affecting the company’s commercial airplane manufacturing output and underscores continuing supply-chain challenges in the aerospace sector. The article provides no financial figures or stock-price impact. https://www.openbell.ai/news/SPCX:1793010703000 2026-10-26T10:31:43.000Z daily 0.9 https://cdn.brandfetch.io/SPCX/w/400/h/400?c=1idopYfmtR7ZKg8QMud SpaceX Secures $40 Billion in Debt Financing for AI Infrastructure SpaceX secured $40 billion in debt financing to purchase Nvidia GPUs and expand its AI and data center operations, according to reports dated October 26, 2026. CEO Elon Musk confirmed the financing, which the company plans to support alongside revenue from Starlink and launches. The investment is intended to strengthen SpaceX’s AI computing capacity and position it in the growing AI infrastructure market.